Heru Prime Diagnostic Platform Showcased at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Seattle, Garnering Praise for Exceptional Diagnostic Performance

MIAMI--(BUSINESS WIRE)--Heru Inc., in collaboration with the Bascom Palmer Eye Institute, presented outstanding clinical data in four clinical studies at the ARVO meeting in Seattle, highlighting Heru Prime’s exceptional diagnostic capabilities. Heru is a medical software company spun out of the Bascom Palmer Eye Institute, the “Best Eye Hospital” in the U.S. according to U.S. News and World Report, with exclusive licenses for more than 50 patents and with a mission to democratize high quality vision care by digitizing and automating eye exams, making them accessible anytime, anywhere. The clinical studies demonstrated Heru’s new diagnostic applications' remarkable diagnostic accuracy and performance across multiple eye assessments, reaffirming Heru's commitment to revolutionizing vision diagnostics.

The presented clinical data emphasized the patient-centric design of Heru's platform. Heru’s Al-powered solution runs on virtual reality (VR) headsets to digitize and automate eye tests once done manually by doctors and technicians, replacing capital-intensive medical grade vision diagnostic furniture. Before Heru, there was no efficient, consistent, and trusted way to conduct manual eye tests.

"Eye care professionals can rely on Heru's innovative diagnostic platform to deliver precise results for their patients, while streamlining workflows and expanding access to care," said Mohamed Abou Shousha, M.D., Ph.D., FRCS, Chief Executive Officer and Founder of Heru. "Our platform, Heru Prime, offers excellent reproducibility and shorter testing times as a vision care diagnostic platform."

Clinical Outcomes:

Clinical Study #1: “A Wearable Approach to RAPD (Relative Afferent Pupillary Defect) Detection: Using a Virtual Reality Headset for Pupillometry”. The clinical study describes and evaluates Heru’s pupil test to determine relative afferent pupillary defects (RAPD). Data analysis proved that the pupil test has an accuracy of 97%, sensitivity of 94% and specificity of 100%. The study concluded that the Heru pupil exam has excellent diagnostic performance.

Clinical Study #2: “Ocular Alignment Evaluation Using a Novel Software Application Running on a Virtual Reality Headset”. The clinical study evaluates the use of Heru’s cover test in assessing ocular alignment. The study demonstrated that Heru’s cover test differentiated between the alignment statuses of ortho, phoria, and tropia patients in a highly significant manner compared to the clinical diagnosis (P<0.001) and that the magnitude of the tropia measured using the digital cover test strongly correlated with that measured clinically (r=0.813; P<0.001, Pearson correlation). The study concluded that the ocular deviation measured with the Heru cover test correlates strongly with the clinically measured ocular deviation.

Clinical Study #3: “Assessment of the Reliability of Pupillometer Measurements Obtained from a Virtual Reality Headset: A Control Subject Analysis”. The clinical study evaluates the reliability of pupillometer measurements obtained by Heru’s pupil test. Excellent repeatability was noted for pupil size in dim and bright light and pupillary reactivity categories. The study concluded that the Heru pupillometer provides consistent and reproducible pupillometry results, proving its potential as a reliable tool for pupillary assessment.

Clinical Study #4: “Evaluating the Efficacy of an AI-Based Algorithm in Streamlining Visual Field Testing: A Comparative Study with SITA Standard Strategy”. The clinical study evaluates the efficiency of Heru re:Imagine visual field-testing strategy, a proprietary artificial intelligence (AI) system-based algorithm, in reducing the time required for visual field testing compared to the Zeiss Humphrey visual field (HFA) SITA strategy. The clinical study showed that Heru re:Imagine strategy significantly reduced the visual field-testing time compared to the HFA in normal subjects with comparable testing times in glaucoma patients. The Pearson correlation coefficient obtained from both devices was 0.93, p<0.001. The study concluded that the Heru re:Imagine AI system is effective in predicting patient thresholds and thus reducing the time required for visual field testing while maintaining excellent correlation to the Zeiss Humphrey visual field.

About Heru:

Heru Prime (www.SeeHeru.com) is an FDA registered, AI platform that runs on VR headsets to perform digital and automated eye exams. Heru’s platform is backed by 50+ patents and 10 years of research and clinical validation through the University of Miami Bascom Palmer Eye Institute, the “Best Eye Hospital” in the U.S. according to U.S. News and World Report.